Skip to main content

Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy.

Publication ,  Journal Article
Nemunaitis, J; Singer, JW; Buckner, CD; Mori, T; Laponi, J; Hill, R; Storb, R; Sullivan, KM; Hansen, JA; Appelbaum, FR
Published in: Bone Marrow Transplant
January 1991

Twenty-seven patients with lymphoid neoplasia who underwent autologous bone marrow transplant (BMT) and who had received recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) were followed in order to examine the potential long-term consequences of rhGM-CSF. rhGM-CSF (15-240 micrograms/m2/day) was given daily either for 14 or 21 days after marrow infusion. All surviving patients who remained in remission had stable marrow graft function. The actuarial survival rate was 45% and the relapse incidence was 50% at a median of 774 days after autologous BMT. These findings suggest that treatment with rhGM-CSF does not have profound adverse long-term consequences.

Duke Scholars

Published In

Bone Marrow Transplant

ISSN

0268-3369

Publication Date

January 1991

Volume

7

Issue

1

Start / End Page

49 / 52

Location

England

Related Subject Headings

  • Transplantation, Autologous
  • Time Factors
  • Recombinant Proteins
  • Middle Aged
  • Male
  • Lymphoma
  • Immunology
  • Humans
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Graft Rejection
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Nemunaitis, J., Singer, J. W., Buckner, C. D., Mori, T., Laponi, J., Hill, R., … Appelbaum, F. R. (1991). Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy. Bone Marrow Transplant, 7(1), 49–52.
Nemunaitis, J., J. W. Singer, C. D. Buckner, T. Mori, J. Laponi, R. Hill, R. Storb, K. M. Sullivan, J. A. Hansen, and F. R. Appelbaum. “Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy.Bone Marrow Transplant 7, no. 1 (January 1991): 49–52.
Nemunaitis J, Singer JW, Buckner CD, Mori T, Laponi J, Hill R, Storb R, Sullivan KM, Hansen JA, Appelbaum FR. Long-term follow-up of patients who received recombinant human granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for lymphoid malignancy. Bone Marrow Transplant. 1991 Jan;7(1):49–52.

Published In

Bone Marrow Transplant

ISSN

0268-3369

Publication Date

January 1991

Volume

7

Issue

1

Start / End Page

49 / 52

Location

England

Related Subject Headings

  • Transplantation, Autologous
  • Time Factors
  • Recombinant Proteins
  • Middle Aged
  • Male
  • Lymphoma
  • Immunology
  • Humans
  • Granulocyte-Macrophage Colony-Stimulating Factor
  • Graft Rejection